Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26
Wells Fargo analyst Eva Fortea Verdejo maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight and raises the price target from $23 to $26.
Stocks · News reference
Arcus Biosciences Announces Publication In Nature Describing New Research From The ARC-20 Study Showing Casdatifan HIF-2a Inhibition Deeply Suppresses Serum EPO And Extends Progression-Free Survival In Advanced Kidney Cancer
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $41 to $43.
Arcus Biosciences Q2 EPS $(0.72) Beats $(0.87) Estimate, Sales $41.000M Beat $23.405M Estimate
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.87) by 17.24 percent. This is a Infinity percent decrease over earnings of $0.00 per share
Arcus Biosciences Announces A Clinical Supply Agreement With AVEO Oncology To Evaluate Casdatifan; Agreement Supports A New Randomized Cohort Within The ARC-20 Study Evaluating Investigational Casdatifan Plus Tivozanib Versus Tivozanib Alone In Patients Who Received Prior HIF-2α-inhibitor Therapy; Enrollment Expected To Begin In Q4 2026
This agreement supports a new randomized cohort within the ARC-20 study evaluating investigational casdatifan plus tivozanib versus tivozanib alone in patients who received prior HIF-2α-inhibitor therapyEnrollment is